Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents.

Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents. Expert Rev Anti Infect Ther. 2019 Mar 11;: Authors: Wei L, Huang YH Abstract INTRODUCTION: Within the past decade, antiviral treatment for chronic hepatitis C virus (HCV) infection has evolved from interferon (IFN)-based regimens to IFN-free oral direct-acting antiviral agents (DAAs). However, data on long-term outcomes in HCV patients treated by DAAs are limited and complex. This review summarizes the literature on long-term outcomes in patients with chronic HCV infection who received IFN-based and DAA treatment. Areas covered: Original studies and meta-analyses reporting data on the impacts of IFN- and DAA-based treatments on late relapse, liver fibrosis/cirrhosis, decompensation progression, hepatocellular carcinoma (HCC) occurrence and recurrence, need for liver transplantation, mortality, and other topics of interest for long-term observation of HCV patients treated with DAAs. Articles published up to June 2018, and conference proceedings from the American Association for the Study of Liver Diseases, European Association for the Study of the Liver and the Asian Pacific Association for the Study of the Liver annual meetings (from 2015 to June 2018) were reviewed. Relevant references from selected papers were also reviewed. Expert opinion: In HCV patients treated with DAAs or IFN-based regimens, late relapse beyond 12 week...
Source: Expert Review of Anti-Infective Therapy - Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research